As a result, after the cancer cells were quickly killed by alpha particles from 225Ac, the radiation from the actinium and its daughters might induce new mutations. To solve this problem, 225Ac was bound to a chelating agent, such as citrate, ethylenediaminetetraacetic acid (EDTA) or diethylene triamine pentaacetic acid (DTPA). This reduced actinium accumulation in the bones, but the excretion from the body remained slow.
As a result, after the cancer cells were swiftly destroyed by alpha particles from 225Ac, the radiation produced by the actinium and its decay products might lead to new mutations. To tackle this problem, 225Ac was linked to a chelating agent, like citrate, ethylenediaminetetraacetic acid (EDTA), or diethylene triamine pentaacetic acid (DTPA). This decreased actinium buildup in the bones, but the removal from the body remained slow.